Best Practices for Preventing Drug Diversion and GPO Violations in the 340B Program: Tools and Policies for Healthcare Entities

The 340B Drug Pricing Program helps healthcare organizations provide medications at discounted rates. This support allows them to use their resources more effectively. However, strict compliance with federal guidelines is necessary for the program’s integrity. Medical practice administrators, owners, and IT managers in the United States should actively work to prevent drug diversion and violations of Group Purchasing Organization (GPO) rules. This article presents key practices and tools for healthcare entities to remain compliant and avoid penalties.

Understanding Drug Diversion

Drug diversion happens when medications intended for eligible patients are given to those who do not qualify. This situation can arise in various ways, such as dispensing drugs to non-patients, using medications outside eligible facilities, or not keeping accurate patient records. The Health Resources and Services Administration (HRSA) is responsible for overseeing compliance for the 340B Program and conducts around 200 audits each year to ensure compliance. Understanding drug diversion is important for adherence to guidelines.

Key Compliance Areas

• Eligibility Verification: Healthcare entities must confirm patient eligibility before dispensing drugs under the 340B Program. This means following the Patient Definition Guidelines from HRSA, which specify who qualifies as a patient. Regular audits and checks against HRSA definitions are essential to ensure that only eligible patients benefit from the program.
• Preventing Duplicate Discounts: Organizations must avoid receiving both a 340B discount and a Medicaid rebate for the same drug for an eligible patient. Monitoring claims carefully and understanding how to apply “carve in” and “carve out” strategies is key. For instance, “carving out” means not using 340B drugs for Medicaid patients under fee-for-service arrangements to prevent duplicate discounts.
• Record-Keeping and Tracking: Maintaining accurate records is essential for compliance. Entities must create a strong tracking system to monitor all 340B drug distributions and ensure they go to eligible patients. Conducting regular internal audits is vital to compare drug administration records with eligibility information to find any discrepancies.

GPO Prohibitions and Compliance

Group Purchasing Organizations (GPOs) can help healthcare entities save costs, but their use must align with 340B Program rules. Covered entities are not allowed to buy 340B drugs through GPOs, as this compromises their eligibility for the program.

Strategies to Prevent GPO Violations

• Education and Training: Medical practice administrators should ensure that staff understand the prohibition against GPO purchasing in the 340B Program. Staff must be trained on what purchasing practices are acceptable and the risks of non-compliance.
• Purchasing Policies: Setting clear purchasing policies is important. These policies should outline how medications can be obtained under the 340B Program. They should be reviewed and updated regularly to reflect any changes in regulations or HRSA auditing practices.
• Data Analytics: Using data analytics can enhance monitoring and compliance efforts. Systems should be in place to analyze purchasing patterns against GPO transaction data, helping to identify potential violations before they occur.

Utilizing Technology and Data Analytics

The 340B Program can be complex, and healthcare entities can benefit from using technology and data analytics in compliance efforts. Data analytics allows for thorough testing of program data rather than relying on smaller sample sizes. This approach helps identify compliance issues more effectively.

How Data Analytics Facilitates Compliance

• 100% Testing: Data analytics tools enable auditors to analyze all transactions, linking patient records with drug distributions. Access to complete data helps organizations identify discrepancies early, thus avoiding major issues.
• Automated Alerts: Software solutions can send alerts for transactions not meeting 340B criteria. For example, if an ineligible patient is identified in the database or if a GPO purchase is attempted, the system can alert administrators quickly.
• Reporting Capabilities: Advanced analytics solutions provide reporting features that allow tracking of compliance metrics. Regular reporting aids organizations in maintaining accountability and transparency, which is crucial for audits.

AI and Workflow Automation: Enhancing Efficiency and Compliance

Integrating AI and workflow automation in healthcare operations can help prevent drug diversion and GPO violations. AI can simplify many existing processes that involve extensive manual work.

Automating Patient Eligibility Verification

AI algorithms can assess patient records to determine eligibility for the 340B Program. By comparing patient information with HRSA guidelines, AI can automate the initial verification stage, which reduces errors and saves time for staff.

Streamlining Auditing Procedures

Workflow automation can streamline auditing processes by extracting and compiling data automatically from various sources. Less time spent on data collection means staff can concentrate on analyzing compliance metrics and improving efficiency.

Intelligent Reporting Tools

AI-powered reporting tools can generate real-time compliance reports, providing an overview of drug distributions, patient eligibility, and purchasing activities. These tools can identify potential issues, allowing healthcare entities to address concerns proactively.

Best Practices for Compliance and Risk Management

Healthcare organizations should adopt several best practices to prevent drug diversion and GPO violations effectively:

• Implement Internal Audits: Regular internal audits are essential for reviewing compliance with 340B regulations. Auditors should confirm that the organization meets eligibility standards and there are no discrepancies in drug distribution records.
• Establish a Compliance Committee: Creating a compliance committee with representatives from various departments, such as pharmacy, finance, and legal, can oversee compliance efforts, conduct training, and monitor adherence to practices and policies.
• Develop a Compliance Culture: Building a culture of compliance requires promoting accountability throughout the organization. This can be achieved through ongoing education, open communication, and recognition of staff contributions to compliance efforts.
• Utilize Self-Audit Tools: Healthcare entities can use self-audit resources from HRSA, like sample manuals. These tools help develop effective compliance programs tailored to specific needs.
• Continuous Training and Education: Ongoing training opportunities are crucial for all staff involved in the 340B Program. Keeping staff updated on regulation changes helps ensure they remain vigilant and informed.

Navigating the Legal Landscape

The compliance landscape of the 340B Program is further complicated by ongoing legal issues related to contract pharmacy pricing and other matters. Organizations must stay informed about legal developments that may affect their operations. Understanding significant legal cases can guide compliance strategies and highlight areas of increased risk.

Final Review

Preventing drug diversion and GPO violations in the 340B Program requires a comprehensive approach that emphasizes adherence to compliance guidelines and the use of technology for efficiency. By creating practical policies, investing in technology, and promoting a culture of accountability, healthcare organizations can effectively manage the complexities of the 340B Program. Diligent effort and an emphasis on continuous improvement can help entities serve the populations that rely on their services.